Innovation in the Sample Preparation Market

Wednesday, March 1, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 1, 2017 /PRNewswire/ --

A research report by Markets and Markets indicates that the sample preparation

market is forecasted to reach approximately USD 7.2 billion in sales by 2021, from about USD 5.5 billion in 2016, growing at CAGR of 5.5%. In the medical field sample preparations refers to
the ways in which a sample is treated prior to testing. Preparation is a very important step in most analytical techniques. The expected growth is due to an increase in laboratory and R&D spending, global alliances among leading research institutes to boost innovation and trials, a strong desire to meet the unmet need for food analysis due to safety concerns, as well as rising adoption of modern extraction techniques. Pressure BioSciences, Inc. (OTC: PBIO), Danaher Corporation (NYSE: DHR), Illumina Inc. (NASDAQ: ILMN), PerkinElmer Inc. (NYSE: PKI), Agilent Technologies Inc. (NYSE: A)  

The research also indicates that a shift from the more traditional manual techniques, to automated sample preparation is a major factor contributing to the sample preparation market. Mass spectrometry (MS) is a highly selective analytic technique which provides significantly more accurate measurements and as a result, is now being used in an increasing number of clinical laboratories. MS ionizes chemical species and sorts the ions based on mass to charge ratio. It can be used in various fields, applied to pure samples and complex mixtures.  

Pressure BioSciences, Inc. (OTCQB: PBIO) is the developer and seller of broadly enabling, pressure cycling technology ("PCT") - based sample preparation solutions to the worldwide life sciences industry. Earlier today the company announced that, "its Barocycler 2320EXTREME ("2320EXT") has been named the "Best New Instrument for Sample Preparation 2017" by Corporate America News ("Corp America") as part of the publication's 2017 North American Excellence Awards. With a subscription list of more than 135,000 business and professional service providers, Corp America is a leading magazine in the U.S business market. The magazine's annual North American Excellence Awards honor companies and individuals who tirelessly work to drive innovation and exhibit true passion for their work.

The award-winning, next generation Barocycler 2320EXT is the latest addition to PBI's Barocycler family. It is a compact, bench top instrument offering many advanced features and benefits.  These and other additions have already positioned the Barocycler 2320EXT as an instrument of choice for life science key opinion leaders ("KOLs") worldwide, when preparing protein samples for analysis.  

Dr. Nate Lawrence, Vice President of Marketing and Sales for PBI, said: "We are honored to have been selected for this prestigious award.  It was just eight months ago when we launched this next-generation Barocycler instrument, the 2320EXT. Since then, the instrument has been purchased by key scientists in academic, government, biotech and pharma labs worldwide, including institutions involved in the Cancer Moonshot Initiative. We believe this award affirms the significant potential of the Barocycler 2320EXT."

ProCan, a cancer research initiative located in the Children's Medical Research Institute near Sydney Australia, and a Cancer Moonshot collaborator, purchased three Barocycler 2320EXTs in June 2016. At the time of their purchase, Professor Phil Robinson, co-head of ProCan, said: "Patient tumor samples can be pretty tiny and very heterogeneous, but the use of PCT in sample preparation allows researchers to analyze tissue samples as small as those provided by needle biopsies.  So you can use incredibly small amounts of tissue, reliably digest them in a couple of hours, and get large amounts of information with the Barocycler 2320EXT."

Professor Ruedi Aebersold, a world-renowned protein chemist who recently upgraded to the Barocycler 2320EXT, emphasizes the importance of sample preparation in the article. Dr. Aebersold said: "Not only do we need to consider the method of analyzing the proteome, but we must also recognize that the method of sample preparation used to optimize protein extraction & digestion is equally as important."

Dr. Lawrence commented: "It is the support of KOLs like Professors Robinson and Aebersold that we believe helped convince the panel of judges that the Barocycler 2320EXT deserved to win the 2017 North American Excellence Award for Best New Sample Preparation Instrument."

PBI President and CEO Richard T. Schumacher was interviewed by the magazine upon selection of the award. In a four-page article, Mr. Schumacher provides an in-depth overview of PBI's patented PCT technology and its unique advantages, the Company's history of innovation and growth, its large market opportunity, additional features and benefits of the 2320EXT, the recent co-marketing agreement with global life sciences leader SCIEX, and his expectations that significant growth is on the horizon. To view the full article, visit and turn to page 8.

Pressure BioSciences, previously announced an exclusive co-marketing agreement with SCIEX, a company focuses on science analytical technologies, and a wholly-owned subsidiary of Danaher Corporation (NYSE: DHR). Under the agreement, the companies will jointly promote Pressure BioSciences' PCT-based sample preparation systems and SCIEX's mass spectrometry equipment, with a focus on improved sample preparation. Danaher offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company's goal is to make diagnosis within 24 hours of a biopsy possible. Danaher operates in five segments: Test & Measurement, Environmental, Life Sciences & Diagnostics, Dental, and Industrial Technologies.

Illumina Inc. (NASDAQ: ILMN) is a provider of sequencing- and array-based solutions for genetic analysis. The company's product, TruSeq® DNA PCR-Free Library Preparation Kits provide simple, all-inclusive library preparation for whole-genome sequencing applications. Researchers can sequence a wide variety of organisms, from small genomes such as bacteria to human whole-genomes. The kits offer shortened gel-free workflows that remove the need for PCR, the ability to sequence the most challenging regions and improved genome coverage to identify the greatest number of variants. By removing PCR, it creates a faster protocol and superior data quality.

PerkinElmer Inc. (NYSE: PKI) is a provider of products, services and solutions to the diagnostics, research, environmental and laboratory markets. The company provides with a portfolio of sample preparation supplies that ensures successful preparation, including consumables for microwave digestion systems, Sample Preparation Blocks (SPBs), and Solid Phase Extraction (SPE) for a broad range of applications. The company's Human Health segment concentrates on developing diagnostics, tools and applications to help detect diseases earlier. Within its Human Health segment, the Company serves the diagnostics and research markets.

Provider of application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow, Agilent Technologies Inc. (NYSE: A) offers sample preparation products that help achieve analytical goals. The company offers syringe filters with a complete membrane portfolio for all sample types. Other Captiva products include cartridges and plates for protein precipitation workflows. For more complex needs, Bond Elut solid phase extraction (SPE) products feature sorbents with phases for different analyte extraction and cleanup needs. QuEChERS kits include extraction salts and dispersive SPE tubes ideal for food applications.

Please SIGN UP NOW at To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. only regurgitates financial or corporate news through our unique financial newswire and media platform. expects to be compensated ten thousand dollars for financial news dissemination and pr services by pressure biosciences, inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit:

For further information: Media Contact:, +1-877-601-1879



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store